Disturbance of the Intestinal Microbiota by Temocillin vs Cefotaxime in Treatment of Febrile Urinary Tract Infections

A Randomized, Controlled, Multicentre Trial of Collateral Damage on the Intestinal Microbiota Inferred by Temocillin Versus Cefotaxime in Patients Receiving Empirical Treatment for Febrile Urinary Tract Infections

This study will evaluate the ecological impact on the intestinal microbiota and compare the safety and efficacy of temocillin compared to cefotaxime, in empiric treatment of febrile UTI. Half of participants will receive temocillin and the other half will receive cefotaxime.

Study Overview

• Status: Completed
• Conditions: Urinary Tract Infections
• Intervention / Treatment: Drug: Temocillin; Drug: Cefotaxime

Detailed Description

Temocillin is a narrow spectrum antibiotic with activity against gram negative bacteria inclusive many ESBL producing bacteria. Temocillin is approved and marketed in a few European countries since the 1980´s but not in Sweden.

The aim of the study is to find an ecological favorable alternative to cephalosporins in the treatment of this common indication.

The hypothesis is that treatment with temocillin causes less disturbances on the intestinal microbiota while at least comparable efficacy.

The study will be performed as an open prospective multicentre study with two parallel groups comparing 2 g temocillin three times daily with 1-2 g cefotaxim three times daily for 7-10 days in male and female adult patients with febrile urinary tract infection.

• Study Type: Interventional
• Enrollment (Actual): 157
• Phase: Phase 4

Contacts and Locations

Study Locations

• Sweden
  • Helsingborg, Sweden, 251 87
    • Helsingborg Hospital
  • Kristianstad, Sweden, 291 85
    • Centralsjukhuset Kristianstad
  • Linköping, Sweden, 581 85
    • Linkoping University Hospital
  • Lund, Sweden, 221 85
    • Skane University Hospital
  • Norrköping, Sweden, 601 82
    • Vrinnevisjukhuset i Norrköping
  • Stockholm, Sweden, 112 81
    • Capio S:t Görans Hospital
  • Sundsvall, Sweden, 856 43
    • Sundsvall Hospital
  • Umeå, Sweden, 901 85
    • University Hospital of Umeå
  • Västerås, Sweden, 721 89
    • Västmanlands sjukhus i Västerås
  • Örebro, Sweden, 701 85
    • Orebro University Hospital
  • Östersund, Sweden, 83131
    • Östersund hospital
  • Stockholm
    • Solna, Stockholm, Sweden, 171 76
      • Karolinska University Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 16 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Males and females ≥ 18 years of age with suspected or confirmed febrile UTI, fulfilling at least one of the following signs and symptoms:

  • Flank pain or suprapubic pain, Tenderness over the kidney on physical examination, Urinary symptoms such as dysuria, urinary frequency or urinary urgency
• Fever ≥ 38.0°C (highest temperature recorded at home or at the hospital)
• Positive urinalysis tests (U-Nitrit and/or U-LPK)
• Have a pre-treatment baseline urinary culture obtained
• Require iv antibacterial treatment of the presumed infection
• Fertile women: Agree to practice highly effective anti-contraceptive methods from study-start to TOC
• Signed informed consent

Exclusion Criteria:

• Have a documented history of hypersensitivity or allergic reaction to any beta-lactam
• Pregnant or nursing women
• Receipt of any prior potentially therapeutic antibacterial agent within 1 month before randomisation and sampling for urine and faecal cultures. Exceptions will prior treatment with pivmecillinam or nitrofurantoin.
• Known chronic renal insufficiency (creatinine clearance < 10 mL/min at screening as estimated by Cockcroft-Gault), or receiving intermittent haemodialysis or peritoneal dialysis
• Known colonization with ESBL
• Any condition or circumstance that, in the opinion of the investigator, would compromise the safety of the subject or the quality of study data.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Temocillin; Temocillin powder for solution för injection/infusion, per day 6 g (2 g three times per day). Treatment length 7-10 days of which at least 3 days administration with the study drug.	Drug: Temocillin; Total antibiotic treatment 7-10 days, of which at least 72 hours (9 doses) initial temocillin administration. In case of bacteraemia at baseline the total antibiotic treatment can be extended up to 14 days.; Other Names: Negaban
Active Comparator: Cefotaxime; Cefotaxime powder for solution för injection/infusion, per day 3-6 g (1-2 g three times per day). Treatment length 7-10 days of which at least 3 days administration with the study drug.	Drug: Cefotaxime; Total antibiotic treatment 7-10 days, of which at least 72 hours (9 doses) initial cefotaxime administration. In case of bacteraemia at baseline the total antibiotic treatment can be extended up to 14 days.; Other Names: Claforan

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of patients with emergence of any of the two following events: Colonisation or infection with C. difficile and/or with Enterobacteriaceae resistant to 3rd generation cephalosporins. Measured in cultures from faecal samples.	Superiority analysis.	Within 12 hours after the last dose of study drug.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of patients with clinical cure in each treatment group.	Clinical cure defined as patient totally recovered with no remaining symptoms of UTI or no recurrence with symptoms or no need of further treatment against the current infection. Non-inferiority analysis.	7-10 days after discontinuation of antibiotic treatment (parenteral and oral).
Number of patients with early clinical response.	Non-inferiority analysis.	Within 12 hours after the 9th dose of study drug.
Bacteriological cure per patient and per pathogen measured as negative urine Culture <1000 CFU/ml.	Non-inferiority analysis.	7-10 days after discontinuation of antibiotic treatment (parenteral and oral).
Early bacteriological response measured as negative urine Culture <1000 CFU/ml.	Non-inferiority analysis.	Within 12 hours after the 9th dose of study drug.
Rate of patients with diarrhea (≥ 3 loose stools per day)		From the first dose of study drug until 7-10 days after discontinuation of antibiotic treatment (parenteral and oral).

Other Outcome Measures

Outcome Measure	Time Frame
Frequency of adverse events	From the first dose of study drug until 4-6 weeks after discontinuation of antibiotic treatment (parenteral and per oral).

Collaborators and Investigators

• Sponsor: Håkan Hanberger
• Investigators: Principal Investigator: Håkan Hanberger, Professor, University Hospital, Linkoeping

Study record dates

Study Major Dates

• Study Start (Actual): May 20, 2016
• Primary Completion (Actual): August 1, 2019
• Study Completion (Actual): August 1, 2019

Study Registration Dates

• First Submitted: October 13, 2016
• First Submitted That Met QC Criteria: November 7, 2016
• First Posted (Estimate): November 9, 2016

Study Record Updates

• Last Update Posted (Actual): September 16, 2019
• Last Update Submitted That Met QC Criteria: September 12, 2019
• Last Verified: September 1, 2019

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Urologic Diseases; Disease Attributes; Infections; Communicable Diseases; Urinary Tract Infections; Anti-Infective Agents; Anti-Bacterial Agents; Cefotaxime; Cefoxitin; Temocillin
• Other Study ID Numbers: FoHM/UVI 2015; 2015-003898-15 (EudraCT Number)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No